FPRX Five Prime Therapeutics Inc.

5.59
-0.07  -1%
Previous Close 5.66
Open 5.68
Price To Book 0.86
Market Cap 201,589,811
Shares 36,062,578
Volume 214,619
Short Ratio
Av. Daily Volume 540,513

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 futility analysis due 1H 2020.
FPA144 + chemo (FIGHT)
Gastric and gastro-esophageal junction cancer
Phase 1b ongoing.
Cabiralizumab (FPA008) and Opdivo (nivolumab)
Solid tumors
Phase 2 complete. Phase 3 development will not be pursued.
Cabiralizumab (FPA008)
Pigmented Villonodular Synovitis (PVNS)
Phase 1b NSCLC halted, mesothelioma to continue. Data at ESMO showed ORR 48%.
FP-1039
Mesothelioma cancer
Phase 1b initial data due at ESMO 27 September-1 October 2019.
FPA150
Solid tumors
Phase 2 trial initiated January 2018.
Cabiralizumab (FPA008) and Opdivo (nivolumab)
Pancreatic cancer
Phase 1 dosing announced November 14, 2018. Data due 2019.
FPT155
Solid tumors

Latest News

  1. Estimating The Fair Value Of Five Prime Therapeutics, Inc. (NASDAQ:FPRX)
  2. Five Prime Therapeutics Appoints Lori Lyons-Williams to its Board of Directors
  3. Is Five Prime Therapeutics Inc (FPRX) A Good Stock To Buy?
  4. Five Prime Therapeutics (FPRX) Looks Good: Stock Adds 9.2% in Session
  5. See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.
  6. Five Prime Therapeutics Announces the Departure of Dr. Sheila Gujrathi From its Board of Directors
  7. Five Prime Therapeutics to Present at Two Upcoming Healthcare Conferences
  8. Five Prime Therapeutics Presents Monotherapy Data From the Phase 1a/1b Trial of FPA150 in Patients With Advanced Solid Tumors at the 2019 ASCO Annual Meeting
  9. Edited Transcript of FPRX earnings conference call or presentation 8-May-19 8:30pm GMT
  10. Five Prime Therapeutics Appoints Carol Schafer to its Board of Directors
  11. Five Prime Therapeutics Announces FPA150 Poster Presentation at the 2019 ASCO Annual Meeting
  12. Five Prime Therapeutics (FPRX) Q1 2019 Earnings Call Transcript
  13. Five Prime Therapeutics (FPRX) Reports Q1 Loss, Misses Revenue Estimates
  14. Five Prime Therapeutics: 1Q Earnings Snapshot
  15. Five Prime Therapeutics Reports First Quarter 2019 Results
  16. Earnings Preview: Five Prime Therapeutics (FPRX) Q1 Earnings Expected to Decline
  17. Can 'synthetic lethality' and deep experience propel this cancer-fighting biotech's $70M IPO?